Medtronic Touts In.Pact Admiral DCB Data

Monday, November 2, 2015

Source: MassDevice

Medtronic (NYSE:MDT) today touted data from a pair of studies of its In.Pact Admiral drug-coated balloon, presented today at the annual Vascular Interventional Advances conference in Las Vegas.

Researchers revealed the formal cost-effectiveness analysis of the U.S. cohort of Medtronic’s In.Pact SFA trial, and in-stent restenosis cohort data from its In.Pact Global study.

Medtronic said the 2-year, prospective cost-effectiveness study of 181 patients showed that, although treatment with the drug-coated balloon was more expensive than with standard percutaneous transluminal angioplasty, costs were actually $100 lower over 2 years of follow-up, as the DCB-treated arm showed a significantly lower rate of target limb revascularization procedures. Index hospitalization costs with In.Pact Admiral were $8,293, compared with $7,164 for the PTA arm. That was offset by a reduction in follow-up costs for the DCB-treated group, at $2,984 over 2 years compared with $4,196 for the control group.

View All News »